Successful transurethral intralesional BCG therapy of a bladder melanoma
Open Access
- 1 November 1975
- Vol. 36 (5) , 1662-1667
- https://doi.org/10.1002/1097-0142(197511)36:5<1662::aid-cncr2820360520>3.0.co;2-6
Abstract
An isolated metastasis of malignant melanoma to the urinary bladder of a patient was successfully eradicated by transurethral intralesional injection of BCG. Total destruction of the tumor was confirmed by subsequent excision. Lymphocyte blastogenesis studies revealed no significant alteration in immunocompetence secondary to the therapy, except for an increased responsiveness to PPD. There was no evidence of presence of blocking factors following therapy; cytotoxicity against MLA‐14 melanoma cells sharply increased after the intralesional injection. Humoral antimelanoma antibody levels, determined by complement fixation, were decreased before the intralesional therapy, but increased markedly immediately following the transurethral BCG injection.Keywords
This publication has 12 references indexed in Scilit:
- Complications of BCG Immunotherapy in Patients with CancerNew England Journal of Medicine, 1973
- GRANULOMATOUS HEPATITIS: A COMPLICATION OF B.C.G. IMMUNOTHERAPYThe Lancet, 1973
- ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMAThe Lancet, 1973
- BCG Vaccination and Leukemia MortalityJAMA, 1972
- ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIAThe Lancet, 1969
- Treatment of Metastatic Melanoma of the BladderJournal of Urology, 1966
- Melanoma of the Genitourinary TractJournal of Urology, 1965
- Metastatic Melanoma of the BladderJournal of Urology, 1964
- Primary and Secondary Melanoma of the Genitourinary TractSouthern Medical Journal, 1958
- Study of the Bladder Tumors in the Registry of the American Urological AssociationJournal of Urology, 1950